You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 12, 2025

Claims for Patent: 11,744,816

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,744,816

Title:	Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
Abstract:	Disclosed herein are compositions comprising fixed doses of ETC-1002 and Ezetimibe. Also disclosed herein are methods for using fixed doses of ETC-1002 and Ezetimibe. Uses include methods of treating cardiovascular disease or reducing the risk of cardiovascular disease in a subject. Uses also include methods of treating hypercholesterolemia in a subject.
Inventor(s):	Roger Schofield Newton, Noah Laban Rosenberg, Diane Elaine MacDougall
Assignee:	Esperion Therapeutics Inc
Application Number:	US17/136,870
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,744,816
Patent Claims:	1. A method of lowering LDL-C in a subject in need thereof, the method comprising administering 180 mg 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and 10 mg Ezetimibe to the subject, wherein the subject has familial hypercholesterolemia. 2. The method of claim 1, wherein the 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and Ezetimibe are administered to the subject as a fixed-dose combination. 3. The method of claim 1, wherein administering the 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and Ezetimibe decreases the level of C-reactive protein (hsCRP) in the subject. 4. The method of claim 1, wherein administering the 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and Ezetimibe reduces the very low density lipoprotein in the subject. 5. The method of claim 1, wherein administration of the 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and Ezetimibe reduces the risk of a cardiovascular disease in the subject. 6. The method of claim 1, wherein the 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and Ezetimibe are administered once daily to the subject. 7. The method of claim 2, wherein the fixed-dose combination of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and Ezetimibe is formulated to be a tablet. 8. The method of claim 1, wherein the subject is human.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.